A 35-month remission in a single patient is shedding light on a rare and confusing leukemia diagnosis. The case involved a person with Philadelphia chromosome-positive leukemia, a type of blood cancer. Doctors treated them with a tyrosine kinase inhibitor combined with chemotherapy. The patient achieved complete remission and maintained a deep molecular response for nearly three years.
The case also prompted a review of existing literature. The goal was to help doctors distinguish between two conditions that look alike under the microscope: chronic myeloid leukemia in blast crisis and a rare form of acute leukemia called Ph+ acute megakaryoblastic leukemia. This distinction matters because treatment approaches differ.
The review found that CML presenting with megakaryoblastic blast crisis is very rare, occurring in less than 3% of all CML cases. But because this is a single case report, the findings are not proof that this treatment will work for everyone. More research is needed to confirm the approach.
Common questions
What is Philadelphia chromosome-positive leukemia?
It is a type of blood cancer where cells have a specific genetic change called the Philadelphia chromosome. This change is most common in chronic myeloid leukemia (CML) but can also occur in other leukemias. The case report focused on patients with this chromosome.
How is this case different from other leukemia treatments?
The patient received a tyrosine kinase inhibitor combined with chemotherapy. This combination is used for some leukemias, but the case highlights its use in a rare subtype. Because it is a single case, it does not prove this is the best treatment for everyone.
What does 'deep molecular remission' mean?
It means that a very sensitive test could not find many leukemia cells in the patient's blood or bone marrow. In this case, the level was MR5, which is a very low amount of the BCR::ABL1 gene. The patient stayed at this level for 35 months.
Why is it important to distinguish between CML blast crisis and Ph+ AML?
These two conditions look similar under a microscope but may need different treatments. The case report and review aim to help doctors tell them apart so patients get the right therapy. However, more research is needed to confirm the best approach.
